These DRT radiation nanomedicines were intended to overcome receptor heterogeneity in BC tumours and exploit the co-expression of HER2 and EGFR by some trastuzumab-resistant BC cells (Gallardo et al. 2012). Here, ERBB2 is linked to breast cancer.